Molecular rationale for ERK and EGFR inhibition in colorectal cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.679
Abstract: 679Background: Mutational activation of the RAS pathway occurs in >50% of human CRC tumors, and to date has been difficult to overcome. We recently identified receptor tyrosine phosphatase-S (PTPRS) as an important regulator of the… read more here.
Keywords: erk egfr; cell lines; crc; cancer ... See more keywords